Drug intelligence / Profile preview

inosine + amino acids + peptides

Development stage
Unknown
Lead developer
Heilongjiang Jiangshi Pharmaceutical
Modality
Peptides, Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

安珐布 (Anfabu), also known as Inosine and Amino Acids and Peptides for Injection (注射用肌氨肽苷), is a combination biological product developed and manufactured by Heilongjiang Jiangshi Pharmaceutical. It contains inosine, various amino acids, and peptides derived from animal tissues (typically porcine or bovine). The drug is primarily used in China as a neurotrophic and supportive treatment for a range of neurological and muscular conditions, including cerebral infarction, cerebral hemorrhage, traumatic brain injury, and muscle atrophy. While its exact molecular mechanism is not fully elucidated, it is thought to promote nerve cell metabolism, facilitate the repair of damaged neural tissue, and provide essential building blocks for protein synthesis in muscle and nerve cells. It is administered via intravenous or intramuscular injection.

Brand names
安珐布Anfabu
Other names
注射用肌氨肽苷Inosine and Amino Acids and Peptides for Injection
02

Targets

BCAT (Branched-chain-amino-acid transaminase 1)ANPEP (Aminopeptidase N)ENT1 (Solute carrier family 29 member 1)ADORA1 (Adenosine receptor A1 subtype)PNP (Purine nucleoside phosphorylase)ADA (Adenosine deaminase)

Beyond the preview

Go deeper on inosine + amino acids + peptides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inosine + amino acids + peptides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call